Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2019.12.12

Sai Nxt

Sai Life Sciences announces Sai Nxt, an initiative to transform the organization into a new generation CDMO

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced Sai Nxt, an organization-wide initiative aimed at transforming the company into a new generation CDMO. Guided by the insights and feedback from its customers, the company is investing upwards of US $ 150 million over the period between 2019 and 2023 as a part of Sai Nxt, with a focus on three key areas :

  1. People & culture
  2. Processes & automation
  3. Infrastructure & scientific capabilities

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, “Sai Nxt marks a transformative phase in our journey. Our growth over the years has essentially been driven by our scientific capabilities and customer focus. Raising the bar further, Sai Nxt will help us better serve the growing demand from global innovator pharma and biotech companies for speed and flexibility, with an assurance of compliance and dependability.”

Built on the foundation of partnership, Sai Life Sciences has grown to become one of India’s most trusted CDMOs. Coinciding with the completion of 20 years since its inception, Sai Nxt is the transformative lever aimed to propel the organization in the next phase of its growth.

Sai Nxt initiatives

  1. People & Culture: Expanding scientific talent pool, inducting top-notch global scientific and leadership talent, role-based integrated online training, shop floor transformation, nurturing culture of excellence
  2. Processes & Automation: Process simplification, strengthening governance systems, electronic manufacturing records, IT systems integration, foundation for seamless data capture across operations, leveraging latest technologies (RPA, IOT, AI / ML, AR/ VR) for innovation and intelligence
  3. Infrastructure & Capabilities: Biology lab in Cambridge (MA, USA), Process R&D lab in Manchester (UK), Integrated Discovery and Development campus, expanded suite of technology platforms, early phase delivery facility, flexible manufacturing with 2.5x capacity, advanced safety & quality systems

Through Sai Nxt, the company aims to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

Share article

More News

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more

2025.08.13

Peptide Science & Beyond: Masterclass & Fireside Chat with IISc Professor, Dr. Jayanta Chatterjee

Sai Life Sciences recently hosted Dr. Jayanta Chatterjee, Associate Professor at the Indian Institute of Science (IISc), Bangalore, for two enriching sessions at its campus. The first was the Masterclass Lecture Series, where Dr. Chatterjee addressed a group of scientists at Sai Life Sciences on “Our Adventures in the de novo Design of Helical Macrocyclic […]
Read more

2025.08.13

From vendor to vanguard: Reimagining India’s role in global life sciences

In a recent article published in ET Edge titled, ‘From Vendor to Vanguard: Reimagining India’s Role in Global Life Sciences,’ Krishna Kanumuri, MD & CEO, Sai Life Sciences, highlighted India’s rapidly unfolding transformation from a vendor to an innovation leader in the global life sciences ecosystem.You can read the full article here: From vendor to vanguard: […]
Read more